Vaccine Insights is an online, open-access, peer-reviewed journal focused on advances and innovation within vaccine R&D and manufacturing.
Guided by an expert advisory board, the journal brings together leading experts from pharma, biotech, academia, and other key stakeholders to address critical issues and put the latest developments into context.
We address key challenges and explore the latest advances in vaccine development, production, and supply, publishing reviews, commentary, original research articles, and more.. Visit the Vaccine Insights Journal page to access our full collection.
Our informative webinar series provides expert-led discussions covering major developments, emerging technologies, and strategic considerations, designed to foster continued professional growth and collaboration in vaccine science.
Explore our specialised channels for targeted insights into critical areas, including dedicated immune response and clinical update channels essential for effective vaccine development and deployment.
Learn more about our journal’s aims, scope, and publishing guidelines by visiting our detailed aims and scope.
Sign-up for free to gain unlimited access to our extensive collection of articles, webinars, podcasts, news, and interviews, and remain at the forefront of vaccine innovation.
If you’re interested in partnering with us through sponsored content, webinars, articles, or other collaborations, please view our media kit to find out more.
In this issue, Ravi Ganapathy (IVI) offers a comprehensive look at continuous vaccine manufacturing, mapping the bottlenecks, technologies, and regulatory considerations shaping the field. Plus, contributors from CEPI, the IVI Europe Regional Office, and the Novo Nordisk Foundation for Vaccines & Immunity make the case for a formalised Nordic vaccine collaboration.
"Preparedness cannot be built during a crisis, and existing Nordic capabilities should be harmonised during peacetime." – Catherine Fleck-Vidal, International Vaccine Institute Europe Regional Office
"The industry's shift toward process intensification represents not only a technological advancement but also a fundamental transformation in vaccine manufacturing practices – from distinct batch processes to interconnected, data-driven, continuous systems." – Ravi Ganapathy, Senior Director of Vaccine Process Development, IVI